Literature DB >> 20824452

The burden of rare cancers in Europe.

Gemma Gatta1, Riccardo Capocaccia, Annalisa Trama, Carmen Martínez-García.   

Abstract

The burden of rare tumors in Europe is still unknown and no generally accepted definition of them exist. The Surveillance of Rare Cancers in Europe project (funded by the European Commission) aimed at providing a definition of "rare cancer", a list of cancers and rare cancer burden indicators, based on population-based cancer registry data, across Europe. An international consensus group agreed that incidence is the most appropriate indicator for measuring rare cancers frequency and set the threshold for rarity at 6/100,000/year. The list of rare cancers was based on the International Classification of Diseases for Oncology (ICD-O 3rd edition) and it was hierarchically structured in 2 layers based on various combinations of ICD-O morphology and topography codes: layer (1) families of tumors (relevant for the health care organisation) and layer (2) tumors clinically meaningful (relevant for clinical decision making and research). The burden indicators were estimated and are provided in this chapter.

Entities:  

Mesh:

Year:  2010        PMID: 20824452     DOI: 10.1007/978-90-481-9485-8_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  11 in total

1.  Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.

Authors:  Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays
Journal:  Cancer       Date:  2014-11-04       Impact factor: 6.860

2.  Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma.

Authors:  Teruya Kawamoto; Hitomi Hara; Masayuki Morishita; Naomasa Fukase; Yohei Kawakami; Toshiyuki Takemori; Shuichi Fujiwara; Kazumichi Kitayama; Shunsuke Yahiro; Tomohiro Miyamoto; Takuya Fujimoto; Ikuo Fujita; Kenichiro Kakutani; Tomoyuki Matsumoto; Takehiko Matsushita; Takahiro Niikura; Ryosuke Kuroda; Toshihiro Akisue
Journal:  Clin Exp Metastasis       Date:  2020-05-20       Impact factor: 5.150

3.  Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Authors:  Lars H Lindner; Saskia Litière; Stefan Sleijfer; Charlotte Benson; Antoine Italiano; Bernd Kasper; Christina Messiou; Hans Gelderblom; Eva Wardelmann; Axel Le Cesne; Jean-Yves Blay; Sandrine Marreaud; Nadia Hindi; Ingrid M E Desar; Alessandro Gronchi; Winette T A van der Graaf
Journal:  Int J Cancer       Date:  2018-02-14       Impact factor: 7.396

Review 4.  Rare cancers: Challenges & issues.

Authors:  Raveendran K Pillai; K Jayasree
Journal:  Indian J Med Res       Date:  2017-01       Impact factor: 2.375

5.  How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Authors:  Emanuela Marchesi; Celeste Cagnazzo; Irene Quattrini; Martina Piccinni Leopardi; Chiara Villa; Giovanni Grignani; Lorenzo D'Ambrosio; Silvia Stacchiotti; Paolo Giovanni Casali; Piero Picci
Journal:  Clin Sarcoma Res       Date:  2017-02-28

6.  Communication strategies for rare cancers: a systematic review protocol.

Authors:  Catherine Bell; Katie Kerr; Kerry Moore; Charlene McShane; Lesley Anderson; Amy Jayne McKnight; Helen McAneney
Journal:  Syst Rev       Date:  2019-04-23

7.  Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

Authors:  J-Y Blay; C Honoré; E Stoeckle; P Meeus; M Jafari; F Gouin; P Anract; G Ferron; A Rochwerger; M Ropars; S Carrere; F Marchal; F Sirveaux; A Di Marco; L R Le Nail; J Guiramand; G Vaz; J-C Machiavello; O Marco; S Causeret; P Gimbergues; F Fiorenza; L Chaigneau; F Guillemin; J-M Guilloit; F Dujardin; J-P Spano; J-C Ruzic; A Michot; P Soibinet; E Bompas; C Chevreau; F Duffaud; M Rios; C Perrin; N Firmin; F Bertucci; C Le Pechoux; F Le Loarer; O Collard; M Karanian-Philippe; M Brahmi; A Dufresne; A Dupré; F Ducimetière; A Giraud; D Pérol; M Toulmonde; I Ray-Coquard; A Italiano; A Le Cesne; N Penel; S Bonvalot
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

8.  Improved survival using specialized multidisciplinary board in sarcoma patients.

Authors:  J-Y Blay; P Soibinet; N Penel; E Bompas; F Duffaud; E Stoeckle; O Mir; J Adam; C Chevreau; S Bonvalot; M Rios; P Kerbrat; D Cupissol; P Anract; F Gouin; J-E Kurtz; C Lebbe; N Isambert; F Bertucci; M Toumonde; A Thyss; S Piperno-Neumann; P Dubray-Longeras; P Meeus; F Ducimetière; A Giraud; J-M Coindre; I Ray-Coquard; A Italiano; A Le Cesne
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

Review 9.  Current status and perspectives of patient-derived rare cancer models.

Authors:  Tadashi Kondo
Journal:  Hum Cell       Date:  2020-06-14       Impact factor: 4.174

10.  International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective.

Authors:  Emad Shash; Anastassia Negrouk; Sandrine Marreaud; Vassilis Golfinopoulos; Denis Lacombe; Francoise Meunier
Journal:  Ecancermedicalscience       Date:  2013-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.